Related Experiment Video
Updated: Apr 4, 2026

Th17 Inflammation Model of Oropharyngeal Candidiasis in Immunodeficient Mice
Published on: February 18, 2015
Risk of Oral Complications Among IL-17 Inhibitor Users: A Systematic Review and Meta-Analysis
Luling Wang1, Yajuan Cui1, Shuangshuang Wu1
1Department of Oral Medicine, National Center for Stomatology & National Clinical Research Center for Oral Diseases, National Engineering Research Center of Oral Biomaterials and Digital Medical Devices, Peking University School and Hospital of Stomatology, Beijing, China.
Background:
IL-17 inhibitors are increasingly used in dermatologic and autoimmune diseases, yet the risks of associated oral complications remain unclear.
Methods:
PubMed, Embase, Web of Science, and ClinicalTrials.gov were comprehensively searched. The primary outcome was the incidence of oral complications following IL-17 inhibitors therapy. A meta-analysis was conducted using random-effects models.
Results:
A total of 106 clinical trials involving 57,017 participants were included. Oral mucosal infections were the most frequently observed complications. Meta-analysis was performed to evaluate the incidence of oral candidiasis and oral herpes, showing the pooled incidence of 4.73% (95% CI: 3.42-6.22) and 2.94% (95% CI: 2.50-3.42), respectively. Subgroup analysis indicated a higher risk of oral candidiasis with bimekizumab compared to secukinumab. Notably, the meta-analysis for oral candidiasis demonstrated high heterogeneity (I2 = 93.8%). Besides, bacterial odontogenic diseases (dental caries, pulpitis, abscesses, gingivitis, and periodontitis) and neuropathic disorders (trigeminal neuralgia and facial paralysis), neoplasm (lip neoplasms and tongue squamous cell carcinoma), were reported more frequently in IL-17 inhibitors users.
Conclusion:
IL-17 inhibitor administration is associated with an elevated incidence of oral complications, particularly oral candidiasis and herpetic infections, highlighting the importance of clinician awareness and assessment of oral complications during IL-17 inhibitors therapy.
More Related Videos
06:36Effects of Mechanical Methods Used in Peri-implantitis Treatment on Implant Surface Decontamination and Roughness
Published on: March 14, 2025
06:06Adjunctive Diode Laser Therapy and Probiotic Lactobacillus Therapy in the Treatment of Periodontitis and Peri-Implant Disease
Published on: May 9, 2022
Related Concept Videos
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
The Oral Microbiota
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Bioavailability Study Design: Healthy Subjects Versus Patients
Oral Drug Delivery Systems: Introduction